Q1 Financial Summary for the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated)

Performance Overview

The consolidated results for the first quarter of the fiscal year ending December 2026 (January 1 to March 31, 2026) showed net sales of 6.128 billion yen (up 38.5% YoY), operating profit of 2.079 billion yen (up 90.2%), ordinary income of 2.141 billion yen (up 102.1%), and net income attributable to owners of the parent of 1.528 billion yen (up 220.8%). The increase in net sales was mainly due to higher demand for products used in advanced semiconductor packaging substrates, including generative AI-related products. The significant rise in operating profit was driven by increased drug shipments and robust demand for high-profitability products. By segment, sales increased in Japan, Taiwan, Zhuhai, Suzhou, and Thailand, while sales declined in Europe.

Financial Position and Earnings Guidance Revision

As of the end of the first quarter of the fiscal year ending December 2026, total assets were 37,955 million yen, and net assets were 31,627 million yen, with an equity ratio of 83.3%. The consolidated earnings forecast has been revised from those announced on May 12, 2026, for the second quarter cumulative period and the full year, expecting net sales of 24.5 billion yen (up 17.0% YoY), operating profit of 7.6 billion yen (up 32.2%), and net income attributable to owners of the parent of 5.55 billion yen (up 10.4%).